NCT03790332 2025-10-21Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)Pharmacyclics LLC.Phase 1/2 Completed59 enrolled 2 FDA
NCT03112603 2025-08-12A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)Incyte CorporationPhase 3 Completed330 enrolled 32 charts 2 FDA
NCT02195869 2019-07-11Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseasePharmacyclics LLC.Phase 1/2 Completed45 enrolled 13 charts 2 FDA